Drug intelligence / Profile preview

metronidazole + rifampin

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral

Overview

A combination of two antibiotics - metronidazole (a nitroimidazole antibiotic effective against anaerobic bacteria and certain parasites) and rifampin (also called rifampicin) is a bactericidal antibiotic that inhibits bacterial RNA synthesis. This combination has shown synergistic effects in eliminating persistent bacterial populations, particularly dormant Mycobacterium tuberculosis, and has been studied for treatment of tuberculosis and as part of broader antibiotic regimens for hidradenitis suppurativa.

Targets

rpoB (DNA-directed RNA polymerase subunit beta)Neuraminidase

Beyond the preview

Go deeper on metronidazole + rifampin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on metronidazole + rifampin.

Explore the full profile